According to the report, the global chemiluminescence immunoassay (CLIA) analyzers market was valued at US$ 5.04 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030.
According to the report, the global chemiluminescence immunoassay (CLIA) analyzers market was valued at US$ 5.04 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030
Growing Demand for International Accreditations and Result Comparability Using High Throughput Automated Immunoassays and Increase in Prevalence of Chronic Diseases : Key Drivers of Global Chemiluminescence Immunoassay (CLIA) Analyzers Market
Download Sample @ https://qyresearchmedical.com/sample/111617
Sedentary lifestyle and unhealthy diet is leading to surge in prevalence & incidence of chronic diseases. For instance, according to World Health Organization (WHO), in 2018 cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths globally.
Chronic disease prevalence has increased over time due to an aging population. Moreover, smoking, and body mass index, which are widely known risk factors for chronic diseases such as cancer, cardiovascular disease, etc. thus rise in prevalence of various chronic diseases propel the growth of market
Moreover, major focus of physicians and pathologists operating in in-patient or out-patient settings of the chemiluminescence immunoassay (CLIA) analyzers market is to improve the rate of standardization of the assays. The main objective behind calibration of the assays is to compare the results of the test to the well-established standards while handing out the test results to patients.
The CLIA instruments are closed system multiplexed automated analyzers along with high throughput. These systems are relatively easy to calibrate. The CLIA analyzers are manufactured as per guidelines set by regulatory authorities. The CLIA test manufacturers also offer internal reference standard material to make their results more comparable when compared with other manual assay systems.
Thus, growing demand for international accreditations and result comparability using high throughput automated immunoassays is likely to drive the global chemiluminescence immunoassay (CLIA) analyzers market
To address these demands, the industry players are investing in the research and development activities to develop and introduce new products thereby boosting the global chemiluminescence immunoassay (CLIA) analyzers market
Technological Advancements Propel Global Chemiluminescence Immunoassay (CLIA) Analyzers Market Growth
A major technological trend observed in the global chemiluminescence immunoassay analyzers market is the introduction of next-generation integrated immunoassays. For instance, in October 31, 2017, Abbott announced the FDA 510(k) clearance for Alinity ci-series, instruments for clinical chemistry and immunoassay diagnostics. This innovation in multiplexed assays is likely to drive the global CLIA analyzers market during the forecast period
Moreover, major manufacturers operating in the global CLIA analyzers market are involved in the expansion of their test portfolio through continuous research and development activities. For instance, in December 26, 2017, Danaher (Beckman Coulter, Inc.) received FDA clearance for its Access AMH immunoassay, the first immunoassay that uses recombinant human antigens for determination of anti-Müllerian hormone (AMH) levels. The increasing preference for continuous research with an objective of expansion of test portfolio by major as well as emerging players is likely to result in growth of the global CLIA analyzers market during the forecast period
Stuck in a neck-to-neck competition with other brands? Request a custom report on Chemiluminescence Immunoassay (CLIA) Analyzers Market
Fragmented Consumables Market Affecting Profit Margin to Hamper Global Chemiluminescence Immunoassay (CLIA) Analyzers Market
Continuous expansion of test offering portfolio has resulted in increasing number of emerging market players offering test kits for specific test application at affordable prices
Product offering at relatively lower average selling price has resulted in increasing market penetration of local players having wide distribution network in certain geographies
This is imposing pricing pressure on major manufacturers, thereby intensifying competition. Additionally, there are other technology alternatives that are available in the market at relatively lower cost per procedure, which is also affecting the geographic expansion of major players.
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111617/2900
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market: Competitive Landscape
This report profiles major players in the global chemiluminescence immunoassay (CLIA) analyzers market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global chemiluminescence immunoassay (CLIA) analyzers market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global chemiluminescence immunoassay (CLIA) analyzers market are –
- Abbott
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers (Siemens AG)
- Danaher (Beckman Coulter, Inc.)
- DiaSorin S.p.A
- Ortho Clinical Diagnostics (Part of Carlyle Group)
- Shenzhen New Industries Biomedical Engineering Co., Ltd.
- Sysmex Corporation
- Randox Laboratories Ltd.
- Tosoh Corporation
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market: Key Developments
Key players in the global chemiluminescence immunoassay (CLIA) analyzers market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global chemiluminescence immunoassay (CLIA) analyzers market. A few expansion strategies adopted by players operating in the global chemiluminescence immunoassay (CLIA) analyzers market are:
In June 2020, Abbott announced that it has begun supply of its laboratory-based serology blood test for the detection of the antibody, IgG for identification if COVID-19. This is enabled to contribute to ICMR’s COVID-19 antibody testing strategy to use IgG CLIA antibody tests
In January 2018, DiaSorin S.p.A. partnered with QIAGEN N.V. to add the latter’s QuantiFERON-TB diagnostic test to the former’s LIAISON family of fully automated analyzers.
In October, 2017, Abbott announced the acquisition of Alere Inc., a provider of diagnostic devices and services
The report on the global chemiluminescence immunoassay (CLIA) analyzers market discussed individual strategies, followed by company profiles of manufacturers of chemiluminescence immunoassay (CLIA) analyzers. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global chemiluminescence immunoassay (CLIA) analyzers market.
Key Questions Answered in Global Chemiluminescence Immunoassay (CLIA) Analyzers Market Report
- What is the scope of growth for product companies in the global chemiluminescence immunoassay (CLIA) analyzers market?
- What will be the Y-o-Y growth of the global chemiluminescence immunoassay (CLIA) analyzers market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global chemiluminescence immunoassay (CLIA) analyzers market?
- Will North America continue to be the most profitable market for chemiluminescence immunoassay (CLIA) analyzers providers?
- Which factors are anticipated to hamper the growth of the global chemiluminescence immunoassay (CLIA) analyzers market during the forecast period?
- Which are the leading companies in the global chemiluminescence immunoassay (CLIA) analyzers market?
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market – Segmentation
Product
- Analyzers
- Fully automated
- Semi-automated
- Reagents
- Luminophore Markers
- Enzymatic Markers
- Consumables
Application
- Endocrine Disorders
- Oncology
- Infectious Diseases
- Hepatitis and Retrovirus
- Cardiovascular Disorders
- Allergy
- Autoimmunity
- Drug Discovery & Development
- Others
- End-user
- Hospitals
- Clinical Laboratories
- Pharmaceutical & Biotechnology Industries
- Others
- Region
North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111617/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/